Botulism in Children Aged 1–16: What to Do When Initial Antitoxin Fails to Halt Paralysis
In children aged 1–16 presenting with botulism, the first-line approach includes supportive care and weight-based botulinum antitoxin. When paralysis continues to worsen despite that initial treatment, a defined next clinical step exists.
Patient Population
Children aged 1–16 years with botulism. Dosing of botulinum antitoxin heptavalent (BAT) in this age group is weight-based, ranging from 20% to 100% of the adult dose across ten weight categories.
Previous Treatment & Failure Condition
Prior therapy:
Supportive care — including intubation and mechanical ventilation when necessary — plus botulinum antitoxin heptavalent (BAT) by intravenous infusion, dosed according to the child's weight.
Failure criterion:
Persistent worsening of flaccid paralysis after weight-based BAT administration, raising the possibility that the initial dose was insufficient.
Next-Line Approach
When confidence in the botulism diagnosis is high and paralysis continues to progress after the first antitoxin dose, retreatment with an additional dose of BAT administered by intravenous infusion may be considered.
Full dosing criteria, sequencing, and eligibility details are in the complete protocol.
References
- The BAT dose for children (persons aged 1–16 years) is 20%–100% of the adult dose, according to 10 weight-based categories.
- When confidence in the diagnosis of botulism is substantial, a lack of response to the treatment might indicate that the dose was insufficient, and retreatment should be considered.
- If a child needs a second dose of BAT (a situation that is highly unusual and is clinically indicated by progression of paralysis >24 hours after administration of a first dose of antitoxin, with high confidence in the diagnosis of botulism), the dose is unlikely to result in a hypersensitivity reaction because of sensitization caused by the first dose.
View source ↗